Exodus Point Capital Management, LP Cassava Sciences Inc Transaction History

Exodus Point Capital Management, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 19, 2022	SELL	$17.22 - $38.47 $125,275 - $279,869	-7,275 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$32.6 - $53.05 $237,165 - $385,938	7,275 New	7,275 $270,000
Q4 2021 Feb 11, 2022	SELL	$36.77 - $90.91 $863,616 - $2.14 Million	-23,487 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$41.79 - $135.3 $981,521 - $3.18 Million	23,487 New	23,487 $1.46 Million
Q1 2021 May 17, 2021	SELL	$7.09 - $87.95 $541,938 - $6.72 Million	-76,437 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$6.79 - $12.25 $1.44 Million - $2.6 Million	-211,933 Reduced 73.49%	76,437 $521,000
Q3 2020 Nov 16, 2020	BUY	$2.86 - $11.51 $824,738 - $3.32 Million	288,370 New	288,370 $3.32 Million
Q1 2020 May 15, 2020	SELL	$3.26 - $9.65 $305,722 - $904,977	-93,780 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$1.1 - $6.12 $103,158 - $573,933	93,780 New	93,780 $488,000

185

13.3M

1.38M

2.04M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $1.08B
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.